Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1 4Phase 3 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 2Sarcoma 1NET 1Endocrine 1

Conditions

Neoplasms 4Breast Neoplasms 4Neoplasm Metastasis 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Ovarian Neoplasms 2Osteosarcoma 2Neuroblastoma 2Lymphoma, Mantle-Cell 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma, Synovial 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neutropenia 1Neurofibrosarcoma 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroectodermal Tumors, Primitive 1Multiple Myeloma 1Microphthalmia, Isolated, with Coloboma 5 1Melanoma 1Medulloblastoma 1Lymphoma, T-Cell, Peripheral 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × pegfilgrastim × Clear all
NCT02943733 2022-09-23

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

University of Wisconsin, Madison

Phase 1 Terminated
18 enrolled
EndocrineNET

Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT00004853 2019-11-12

Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
34 enrolled
Sarcoma

Neoplasms, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Sarcoma, Synovial, Neurofibrosarcoma

NCT01214629 2018-08-06

A Study for Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
54 enrolled 23 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT01214642 2018-08-06

A Dose-Escalation Study for Patients With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
63 enrolled 23 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡